Dr. Park on Vemurafenib in Hairy Cell Leukemia

Video

In Partnership With:

Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Memorial Hospital, discusses vemurafenib in hairy cell leukemia.

Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Memorial Hospital, discusses vemurafenib in hairy cell leukemia.

Park says the first breakthrough in hairy cell leukemia came in the 1980s when physicians learned that Pentostatin and Cladribine were highly effective in these patients. In 2011, physicians learned that there was a BRAF V600E mutation in the vast majority of patients with hairy cell leukemia, which gave physicians a promising target.

Based on that finding, Park says, a phase II study is underway looking at vemurafenib, a BRAF inhibitor, in patients with relapsed or refractory hairy cell leukemia.

So far, 13 patients have been accrued for the study. Park says 9 of those patients have completed three months of therapy and 7 of the 9 patients have achieved a complete remission. Park says 2 patients are in partial remission with very little disease burden. All of the patients have a complete hematologic recovery.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD